Document:

Exhibit 10.3

 

SUBSCRIPTION AGREEMENT

 

This SUBSCRIPTION AGREEMENT (this “Subscription
Agreement”) is entered into on April 6, 2021, by and between Mountain Crest Acquisition Corp. II, a Delaware corporation (“MCAD”),
and the undersigned subscriber (the “Investor”).

 

WHEREAS, this Subscription Agreement is being entered
into in connection with the Agreement and Plan of Merger, dated as of the date hereof (as may be amended, supplemented or otherwise modified
from time to time, the “Transaction Agreement”), by and among MCAD, Better Therapeutics, Inc., a Delaware corporation
(the “Company”), and MCAD Merger Sub Inc., a Delaware corporation (“MCAD Merger Sub”), pursuant
to which, among other things, MCAD Merger Sub will merge with and into the Company, with the Company as the surviving company in the merger
and, after giving effect to such merger, the Company being a wholly owned subsidiary of MCAD (the “Transaction”);

 

WHEREAS, in connection with the Transaction, MCAD
is seeking commitments from interested investors to purchase, substantially concurrent with the closing of the Transaction, shares of
MCAD’s common stock, par value $0.0001 per share (the “Shares”), in a private placement for a purchase price
of $10.00 per share;

 

WHEREAS, the aggregate purchase price to be paid
by the Investor for the subscribed Shares (as set forth on the signature page hereto) (the “Acquired Shares”) is referred
to herein as the “Subscription Amount;” and

 

WHEREAS, on
or about the date of this Subscription Agreement, MCAD is entering into subscription agreements substantially similar to this Subscription
Agreement (the “Other Subscription Agreements” and together with this Subscription Agreement, the “Subscription
Agreements”) with certain other investors (the “Other Investors” and together with the Investor, the “Investors”),
pursuant to which the Other Investors, severally, have agreed to purchase additional Shares on the closing date of the Transaction.

 

NOW, THEREFORE, in consideration of the foregoing
and the mutual representations, warranties and covenants, and subject to the conditions, set forth herein, and intending to be legally
bound hereby, each of the Investor and MCAD acknowledges and agrees as follows:

 

1. Subscription.
The Investor hereby irrevocably subscribes for and agrees to purchase from MCAD the number of Shares set forth on the signature page of
this Subscription Agreement on the terms and subject to the conditions provided for herein. The Investor acknowledges and agrees that
MCAD reserves the right to accept or reject the Investor’s subscription for the Shares for any reason or for no reason, in whole
or in part, at any time prior to its acceptance, and the same shall be deemed to be accepted by MCAD only when this Subscription Agreement
is signed by a duly authorized person by or on behalf of MCAD; MCAD may do so in counterpart form.

 

2. Closing.
The closing of the sale of the Shares contemplated hereby (the “Closing”) shall occur on the closing date (the “Closing
Date”) and be conditioned upon the prior or substantially concurrent consummation of the Transaction. Upon delivery of written
notice from (or on behalf of) MCAD to the Investor (the “Closing Notice”), that MCAD reasonably expects all conditions
to the closing of the Transaction to be satisfied or waived on an expected closing date that is not less than five (5) business days from
the date on which the Closing Notice is delivered to the Investor, the Investor shall deliver to MCAD at least (1) business day prior 
to the closing date of the Transaction, the Subscription Amount by wire transfer of United States dollars in immediately available funds
to the account(s) specified by MCAD in the Closing Notice. On the Closing Date, MCAD shall issue the Acquired Shares to the Investor and
promptly cause such Shares to be registered in book entry form in the name of the Investor on MCAD’s share register. In the event
the closing of the Transaction does not occur within two (2) business days of the expected closing date in the Closing Notice, unless
otherwise agreed by MCAD and the Investor, MCAD shall promptly (but not later than two (2) business days thereafter) return the Subscription
Amount to the Investor by wire transfer of U.S. dollars in immediately available funds to the account specified by the Investor, and any
book entries or share certificates shall be deemed cancelled. For purposes of this Subscription Agreement, “business day”
shall mean a day, other than a Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or required
by law to close. Prior to or at the Closing, Investor shall deliver to MCAD a duly completed and executed Internal Revenue Service Form
W-9 or appropriate Form W-8.

 

     

     

    

 

3. Closing
Conditions. The obligation of the parties hereto to consummate the purchase and sale of the Acquired Shares pursuant to this Subscription
Agreement is subject to the satisfaction or valid waiver of the conditions that, on the Closing Date:

 

(a) there
shall not be in force any injunction or order enjoining or prohibiting the issuance and sale of the Shares under this Subscription Agreement,
and no governmental authority of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any judgment, order,
law, rule or regulation which is then in effect and has the effect of restraining, enjoining or otherwise prohibiting the consummation
of the transactions contemplated by this Subscription Agreement;

 

(b) the
terms of the Transaction Agreement (including the conditions thereto) shall have been satisfied (as determined by the parties to the Transaction
Agreement) or waived (other than those conditions which, by their nature, are to be satisfied at the closing of the Transaction), and
the closing of the Transaction shall be scheduled to occur substantially concurrently with or immediately following the Closing;

 

(c) no suspension
of the qualification of the Shares for offering or sale or trading, and no suspension or removal from listing of the Shares on any securities
exchange, shall have occurred, been initiated, or been threatened or notified to the Issuer in writing;

 

(d) with
respect to MCAD’s obligation to close, (i) the representations and warranties made by the Investor in this Subscription Agreement
shall be true and correct in all material respects as of the Closing Date (other than those representations and warranties expressly made
as of an earlier date, which shall be true and correct in all material respects as of such date), without giving effect to the consummation
of the Transactions, and (ii) the Investor shall have performed its obligations and covenants required under this Subscription Agreement
to be performed by it on or prior to the Closing Date (unless such obligation or covenant has been otherwise validly waived);

 

(e) with
respect to the Investor’s obligation to close, (i) the representations and warranties made by MCAD in this Subscription Agreement
shall be true and correct in all material respects as of the Closing Date (other than those representations and warranties expressly made
as of an earlier date, which shall be true and correct in all material respects as of such date), without giving effect to the consummation
of the Transactions, and (ii) MCAD shall have performed its obligations and covenants required under this Subscription Agreement to be
performed by it on or prior to the Closing Date (unless such obligation or covenant has been otherwise validly waived);

 

(f) with
respect to the Investor’s obligation to close, no term of the Transaction Agreement (as in effect on the date hereof) shall have
been amended, modified or waived in a manner that would reasonably be expected to materially adversely affect the economic benefits that
the Investor (in its capacity as such) would reasonably expect to receive under this Subscription Agreement;

 

(g) with
respect to the Investor’s obligation to close, there shall have been no amendment, waiver or modification of any Other Subscription
Agreement that materially benefits any Other Investor thereunder (other than terms particular to the legal or regulatory requirements
applicable to such Other Investor), unless the Investor has been offered substantially the same benefits; and

 

(h) with
respect to the Investor’s obligation to close, MCAD shall have obtained all consents or approvals (including any approval of MCAD’s
shareholders) necessary to permit MCAD to perform its obligations under this Subscription Agreement.

 

4. Further
Assurances. At the Closing, the parties hereto shall execute and deliver such additional documents and take such additional actions
as the parties reasonably may deem to be practical and necessary in order to consummate the subscription as contemplated by this Subscription
Agreement.

 

    2

     

    

 

5. MCAD
Representations and Warranties. MCAD represents and warrants to the Investor that:

 

(a) MCAD
is a Delaware corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware. MCAD has all
power (corporate or otherwise) and authority to own, lease and operate its properties and conduct its business as presently conducted
and to enter into, deliver and perform its obligations under this Subscription Agreement.

 

(b) As of
the Closing Date, the Shares will be duly authorized and, when issued and delivered to the Investor against full payment therefor in accordance
with the terms of this Subscription Agreement, the Shares will be validly issued, fully paid and non-assessable and will not have been
issued in violation of or subject to any preemptive or similar rights created under MCAD’s certificate of incorporation (as in effect
at such time of issuance) or under the Delaware General Corporation Law.

 

(c) This
Subscription Agreement has been duly authorized, executed and delivered by MCAD and, assuming that this Subscription Agreement constitutes
the valid and binding agreement of the Investor, this Subscription Agreement is enforceable against MCAD in accordance with its terms,
except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or
other laws relating to or affecting the rights of creditors generally, or (ii) principles of equity, whether considered at law or
equity.

 

(d) The
issuance and sale by MCAD of the Shares pursuant to this Subscription Agreement will not conflict with or result in a breach or violation
of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance
upon any of the property or assets of MCAD or any of its subsidiaries pursuant to the terms of (i) any indenture, mortgage, deed
of trust, loan agreement, lease, license or other agreement or instrument to which MCAD or any of its subsidiaries is a party or by which
MCAD or any of its subsidiaries is bound or to which any of the property or assets of MCAD is subject that would reasonably be expected
to have a material adverse effect on the business, financial condition or results of operations of MCAD and its subsidiaries, taken as
a whole (a “Material Adverse Effect”), or materially affect the validity of the Shares or the ability of MCAD to comply
in all material respects with its obligations under this Subscription Agreement; (ii) result in any violation of the provisions of
the organizational documents of MCAD; or (iii) result in any violation of any statute or any judgment, order, rule or regulation
of any court or governmental agency or body, domestic or foreign, having jurisdiction over MCAD or any of its properties that would reasonably
be expected to have a Material Adverse Effect or materially affect the validity of the Shares or the ability of MCAD to comply in all
material respects with its obligations under this Subscription Agreement.

 

(e) As of
their respective filing dates, all reports required to be filed by MCAD with the U.S. Securities and Exchange Commission (the “SEC”)
since its initial public offering (the “SEC Reports”) complied in all material respects with the applicable requirements of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations of the SEC promulgated
thereunder. None of the SEC Reports filed under the Exchange Act included, when filed or, if amended, as of the date of such amendment
with respect to those disclosures that are amended, any untrue statement of a material fact or omitted to state a material fact necessary
to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, that MCAD makes
no such representation or warranty with respect to any registration statement or any proxy statement/prospectus to be filed by MCAD with
respect to the Transaction. MCAD has timely filed with the SEC each SEC Report that MCAD was required to file with the SEC. There are
no material outstanding or unresolved comments in comment letters received by MCAD from the SEC (including from the staff of the Division
of Corporation Finance of the SEC) with respect to any of the SEC Reports.

 

(f) Assuming
the accuracy of the representations and warranties of the Investor, MCAD is not required to obtain any consent, waiver, authorization
or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental
authority, self-regulatory organization or other person in connection with the issuance of the Acquired Shares pursuant to this Subscription
Agreement, other than (i) filings with the SEC, (ii) filings required by applicable state securities laws, (iii) the filings required
in accordance with the terms of this Subscription Agreement; (iv) those required by the NASDAQ, including with respect to obtaining approval
of MCAD’s stockholders, and (v) the failure of which to obtain would not be reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect.

 

    3

     

    

 

(g) MCAD
is in compliance with all applicable laws, except where such non-compliance would not reasonably be expected to have a Material Adverse
Effect. MCAD has not received any written communication from a governmental authority that alleges that MCAD is not in compliance with
or is in default or violation of any applicable law, except where such non-compliance, default or violation would not reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect.

 

(h) Except
for such matters as have not had and would not reasonably be expected to have a Material Adverse Effect, there is no (i) suit, action,
proceeding or arbitration before a governmental authority or arbitrator pending, or, to the knowledge of MCAD, threatened in writing against
MCAD or (ii) judgment, decree, injunction, ruling or order of any governmental authority or arbitrator outstanding against MCAD.

 

(i) The
authorized share capital of the MCAD consists, as of the date hereof and as of immediately prior to the closing date of the Transaction,
(i) 30,000,000 shares of common stock, 7,557,500 of which is issued and outstanding and (ii) 1,000,000 shares of preferred stock, 0 of
which is issued and outstanding.

 

(j) MCAD
has not entered into any agreement with any Other Investors relating to such Other Investors’ purchase of the Shares other than
the Other Subscription Agreements entered into with such Other Investors. The Other Subscription Agreements (and any amendments thereto)
reflect the same purchase price per Share and other material terms with respect to the purchase of the Shares are no more favorable to
such Other Investor thereunder than the terms of this Subscription Agreement (other than terms particular to the regulatory requirements
of such Other Investor or its affiliates or related funds).

 

(k) The
Investor, in no circumstances, will be required to pay, reimburse or otherwise be liable for any portion of the fees paid by MCAD to the
Placement Agent (as defined below) or such similar fees.

 

(l) The
issued and outstanding Shares are registered pursuant to Section 12(b)of the Exchange Act and are listed for trading on Nasdaq. There
is no suit, action, proceeding or investigation pending or, to the knowledge of MCAD, threatened against MCAD by Nasdaq or the SEC with
respect to any intention by such entity to deregister the Shares or prohibit or terminate the listing of the Shares on Nasdaq. MCAD has
taken no action that is designed to terminate or is reasonably expected to result in the termination of the registration of the Shares
under the Exchange Act or the listing of the Shares on Nasdaq and is in compliance in all material respects with the listing requirements
of Nasdaq.

 

(m) MCAD
has provided the Investor with a true and correct copy of the Transaction Agreement as in effect on the date hereof.

 

(n) There
are no securities or instruments issued by or to which MCAD is a party containing anti-dilution or similar provisions that will be triggered
by the issuance of (i) the Acquired Shares, (ii) the shares to be issued pursuant to any Other Subscription Agreement or (iii)
the shares to be issued pursuant to the Transaction, in each case, that have not been or will not be validly waived on or prior to the
closing date of the Transaction.

 

6. Investor
Representations and Warranties. The Investor represents and warrants to MCAD that:

 

(a) The
Investor (i) is a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act of 1933, as
amended (the “Securities Act”)) or an institutional “accredited investor” (within the meaning of Rule 501(a)
)(1), (2), (3), (7) or (8) under the Securities Act), in each case, satisfying the applicable requirements set forth on Schedule A,
(ii) is acquiring the Shares only for its own account and not for the account of others, or if the Investor is subscribing for the
Shares as a fiduciary or agent for one or more investor accounts, the Investor has full investment discretion with respect to each such
account, and the full power and authority to make the acknowledgements, representations and agreements herein on behalf of each owner
of each such account, and (iii) is not acquiring the Shares with a view to, or for offer or sale in connection with, any distribution
thereof in violation of the Securities Act (and shall provide the requested information set forth on Schedule A). The Investor
is not an entity formed for the specific purpose of acquiring the Shares and is an “institutional account” as defined by FINRA
Rule 4512(c).

 

    4

     

    

 

(b) The
Investor acknowledges and agrees that the Shares are being offered in a transaction not involving any public offering within the meaning
of the Securities Act, that the Shares have not been registered under the Securities Act and that MCAD is not required to register the
Shares except as set forth in Section 7 of this Subscription Agreement. The Investor acknowledges and agrees that the Shares
may not be offered, resold, transferred, pledged or otherwise disposed of by the Investor absent an effective registration statement under
the Securities Act except (i) to MCAD or a subsidiary thereof, (ii) to non-U.S. persons pursuant to offers and sales that occur
outside the United States within the meaning of Regulation S under the Securities Act or (iii) pursuant to another applicable exemption
from the registration requirements of the Securities Act, and, in each case, in accordance with any applicable securities laws of the
states of the United States and other applicable jurisdictions, and that any certificates representing the Shares shall contain a restrictive
legend to such effect. The Investor acknowledges and agrees that the Shares will be subject to transfer restrictions and, as a result
of these transfer restrictions, the Investor may not be able to readily offer, resell, transfer, pledge or otherwise dispose of the Shares
and may be required to bear the financial risk of an investment in the Shares for an indefinite period of time. The Investor acknowledges
and agrees that the Shares will not immediately be eligible for offer, resale, transfer, pledge or disposition pursuant to Rule 144
promulgated under the Securities Act, and that the provisions of Rule 144(i) will apply to the Shares. The Investor acknowledges and agrees
that it has been advised to consult legal, tax and accounting prior to making any offer, resale, transfer, pledge or disposition of any
of the Shares.

 

(c) The
Investor acknowledges and agrees that the Investor is purchasing the Shares directly from MCAD. The Investor further acknowledges that
there have been no representations, warranties, covenants and agreements made to the Investor by or on behalf of MCAD, the Company, the
Placement Agent, any of their respective affiliates or any control persons, officers, directors, employees, agents or representatives
of any of the foregoing or any other person or entity, expressly or by implication, other than those representations, warranties, covenants
and agreements of MCAD expressly set forth in Section 5 of this Subscription Agreement.

 

(d) The
Investor acknowledges and agrees that the Investor has received such information as the Investor deems necessary in order to make an investment
decision with respect to the Shares, including, with respect to MCAD, the Transaction and the business of the Company and its subsidiaries.
Without limiting the generality of the foregoing, the Investor acknowledges that it has reviewed MCAD’s filings with the U.S. Securities
and Exchange Commission (the “SEC”). The Investor acknowledges and agrees that the Investor and the Investor’s
professional advisor(s), if any, have had the full opportunity to ask such questions, receive such answers and obtain such information
as the Investor and such Investor’s professional advisor(s), if any, have deemed necessary to make an investment decision with respect
to the Shares.

 

(e) The
Investor became aware of this offering of the Shares solely by means of direct contact between the Investor and MCAD, the Company or a
representative of MCAD or the Company, and the Shares were offered to the Investor solely by direct contact between the Investor and MCAD,
the Company or a representative of MCAD or the Company. The Investor did not become aware of this offering of the Shares, nor were the
Shares offered to the Investor, by any other means. The Investor acknowledges that the Shares (i) were not offered by any form of
general solicitation or general advertising and (ii) are not being offered in a manner involving a public offering under, or in a
distribution in violation of, the Securities Act, or any state securities laws. The Investor acknowledges that it is not relying upon,
and has not relied upon, any statement, representation or warranty made by any person, firm or corporation (including, without limitation,
MCAD, the Company, the Placement Agent (as defined below), any of their respective affiliates or any control persons, officers, directors,
employees, agents or representatives of any of the foregoing), other than the representations and warranties of MCAD contained in Section 5
of this Subscription Agreement, in making its investment or decision to invest in MCAD.

 

(f) The
Investor acknowledges that it is aware that there are substantial risks incident to the purchase and ownership of the Shares, including
those set forth in MCAD’s filings with the SEC. The Investor has such knowledge and experience in financial and business matters
as to be capable of evaluating the merits and risks of an investment in the Shares, and the Investor has sought such accounting, legal
and tax advice as the Investor has considered necessary to make an informed investment decision. The Investor acknowledges that Investor
shall be responsible for any of the Investor’s tax liabilities that may arise as a result of the transactions contemplated by this
Subscription Agreement, and that neither MCAD nor the Company has provided any tax advice or any other representation or guarantee regarding
the tax consequences of the transactions contemplated by the Subscription Agreement. The Investor acknowledges that (A) it (i) is a sophisticated
investor, experienced in investing in similar transactions and capable of evaluating investment risks independently, both in general and
with regard to all transactions and investment strategies involving a security or securities and (ii) has exercised independent judgment
in evaluating its participation in the purchase of the Shares and (B) the purchase and sales of the Shares hereunder meet (i) the exemptions
from filing under FINRA Rule 5123(b)(1) and (ii) the institutional customer exception under FINRA Rule 2111(b).

 

    5

     

    

 

(g) Alone,
or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the risks of an investment in
the Shares and determined that the Shares are a suitable investment for the Investor and that the Investor is able at this time and in
the foreseeable future to bear the economic risk of a total loss of the Investor’s investment in MCAD. The Investor acknowledges
specifically that a possibility of total loss exists.

 

(h) In making
its decision to purchase the Shares, the Investor has relied solely upon independent investigation made by the Investor. Without limiting
the generality of the foregoing, the Investor has not relied on any statements or other information provided by or on behalf of the Placement
Agent or any of its affiliates or any control persons, officers, directors, employees, agents or representatives of any of the foregoing
concerning MCAD, the Company, the Transaction, the Transaction Agreement, this Subscription Agreement or the transactions contemplated
hereby or thereby, the Shares or the offer and sale of the Shares.

 

(i) The
Investor acknowledges and agrees that no federal or state agency has passed upon or endorsed the merits of the offering of the Shares
or made any findings or determination as to the fairness of this investment.

 

(j) If the
Investor is not an individual, the Investor has been duly formed or incorporated and is validly existing and is in good standing under
the laws of its jurisdiction of formation or incorporation, with power and authority to enter into, deliver and perform its obligations
under this Subscription Agreement. If the Investor is an individual, the Investor has the authority to enter into, deliver and perform
its obligations under this Subscription Agreement.

 

(k) If the
Investor is not an individual, the execution, delivery and performance by the Investor of this Subscription Agreement are within the powers
of the Investor, have been duly authorized and (i) will not constitute or result in a breach or default under or conflict with any order,
ruling or regulation of any court or other tribunal or of any governmental commission or agency, or any agreement or other undertaking,
to which the Investor is a party or by which the Investor is bound, and will not violate any provisions of the Investor’s organizational
documents, including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership or operating
agreement, as may be applicable and (ii) will not conflict with or result in a breach or violation of any of the terms or provisions of,
or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any of the property or
assets of the Investor or any of its subsidiaries pursuant to the terms of any indenture, mortgage, deed of trust, loan agreement, lease,
license or other agreement or instrument to which the Investor or any of its subsidiaries is a party or by which the Investor or any of
its subsidiaries is bound or to which any of the property or assets of the Investor is subject that would reasonably be expected to have
a material adverse effect on the ability of the Investor to comply in all material respects with its obligations under this Subscription
Agreement.

 

(l) The
signature on this Subscription Agreement is genuine, and the signatory has legal competence and capacity to execute the same or the signatory
has been duly authorized to execute the same, and this Subscription Agreement constitutes a legal, valid and binding obligation of the
Investor, enforceable against the Investor in accordance with its terms except as may be limited or otherwise affected by (i) bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors generally,
and (ii) principles of equity, whether considered at law or equity.

 

(m) Neither
the Investor nor any of its officers, directors, managers, managing members, general partners or any other person acting in a similar
capacity or carrying out a similar function, is (i) a person named on the Specially Designated Nationals and Blocked Persons List,
the Foreign Sanctions Evaders List, the Sectoral Sanctions Identification List, or any other similar list of sanctioned persons administered
by the U.S. Treasury Department’s Office of Foreign Assets Control (“OFAC”), or any similar list of sanctioned
persons administered by the European Union or any individual European Union member state, including the United Kingdom (collectively,
“Sanctions Lists”); (ii) directly or indirectly owned or controlled by, or acting on behalf of, one or more persons
on a Sanctions List; (iii) organized, incorporated, established, located, resident or born in, or a citizen, national, or the government,
including any political subdivision, agency, or instrumentality thereof, of, Cuba, Iran, North Korea, Syria, Venezuela, the Crimea region
of Ukraine, or any other country or territory embargoed or subject to substantial trade restrictions by the United States, the European
Union or any individual European Union member state, including the United Kingdom; (iv) a Designated National as defined in the Cuban
Assets Control Regulations, 31 C.F.R. Part 515; or (v) a non-U.S. shell bank or providing banking services indirectly to a non-U.S.
shell bank (collectively, a “Prohibited Investor”). The Investor represents that if it is a financial institution subject
to the Bank Secrecy Act (31 U.S.C. Section 5311 et seq.) (the “BSA”), as amended by the USA PATRIOT Act of 2001
(the “PATRIOT Act”), and its implementing regulations (collectively, the “BSA/PATRIOT Act”), that
the Investor maintains policies and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. The
Investor also represents that it maintains policies and procedures reasonably designed to ensure compliance with sanctions administered
by the United States, the European Union, or any individual European Union member state, including the United Kingdom. The Investor further
represents that the funds held by the Investor and used to purchase the Shares were legally derived and were not obtained, directly or
indirectly, from a Prohibited Investor.

 

    6

     

    

 

(n) If the
Investor is or is acting on behalf of (i) an employee benefit plan that is subject to Title I of the Employee Retirement Income
Security Act of 1974, as amended (“ERISA”), (ii) a plan, an individual retirement account or other arrangement
that is subject to Section 4975 of the Internal Revenue Code of 1986, as amended (the “Code”), (iii) an entity
whose underlying assets are considered to include “plan assets” of any such plan, account or arrangement described in clauses (i)
and (ii) (each, an “ERISA Plan”), or (iv) an employee benefit plan that is a governmental plan (as defined in
Section 3(32) of ERISA), a church plan (as defined in Section 3(33) of ERISA), a non-U.S. plan (as described in Section 4(b)(4)
of ERISA) or other plan that is not subject to the foregoing clauses (i), (ii) or (iii) but may be subject to provisions under any
other federal, state, local, non-U.S. or other laws or regulations that are similar to such provisions of ERISA or the Code (collectively,
“Similar Laws,” and together with ERISA Plans, “Plans”), the Investor represents and warrants that
(A) neither MCAD nor any of its affiliates (the “Transaction Parties”) has provided investment advice or has otherwise
acted as the Plan’s fiduciary, with respect to its decision to acquire and hold the Shares, and none of the parties to the Transaction
is or shall at any time be the Plan’s fiduciary with respect to any decision in connection with the Investor’s investment
in the Shares; (B) the decision to invest in the Shares has been made at the recommendation or direction of a fiduciary (for purposes
of ERISA and/or Section 4975 of the Code, or any applicable Similar Law) with respect to the Investor’s investment in the Shares
who is independent of the parties to the Transaction; and (C) its purchase of the Shares will not result in a non-exempt prohibited
transaction under Section 406 of ERISA or Section 4975 of the Code, or any applicable Similar Law.

 

(o) The
Investor acknowledges that no disclosure or offering document has been prepared by Cowen and Company, LLC (the “Placement Agent”)
or any of its affiliates in connection with the offer and sale of the Shares.

 

(p) The
Investor acknowledges that none of the Placement Agent, nor any of its affiliates, nor any control persons, officers, directors, employees,
agents or representatives of any of the foregoing has made any independent investigation with respect to MCAD, the Company or its subsidiaries
or any of their respective businesses, or the Shares or the accuracy, completeness or adequacy of any information supplied to the Investor
by MCAD.

 

(q) The
Investor acknowledges that in connection with the issue and purchase of the Shares, none of the Placement Agent or any of its affiliates
have acted as the Investor’s financial advisor or fiduciary.

 

(r) The
Investor, when required to deliver payment to MCAD pursuant to Section 2 above, will have sufficient funds to pay the Subscription
Amount and consummate the purchase and sale of the Shares pursuant to this Subscription Agreement.

 

    7

     

    

 

7. Registration
Rights.

 

(a) MCAD agrees that, within thirty (30) calendar days following the
Closing Date (such deadline, the “Filing Deadline”), MCAD will submit to or file with the SEC a registration statement
for a shelf registration on Form S-1 or Form S-3 (if the Company is then eligible to use a Form S-3 shelf registration) (the “Registration
Statement”), in each case, covering the resale of the Registrable Shares (as defined below) and MCAD shall use its commercially
reasonable efforts to have the Registration Statement declared effective as soon as practicable after the filing thereof, but no later
than the earlier of (i) the 90th calendar day following the filing date thereof if the SEC notifies MCAD that it will
“review” the Registration Statement and (ii) the 5th business day after the date MCAD is notified (orally
or in writing, whichever is earlier) by the SEC that the Registration Statement will not be “reviewed” or will not be subject
to further review (such earlier date, the “Effectiveness Deadline”); provided, however, that MCAD’s obligations
to include the Registrable Shares in the Registration Statement are contingent upon Investor furnishing a completed and executed selling
shareholder’s questionnaire in customary form to MCAD, that contains such information regarding Investor as required by the SEC
rules to be included in the Registration Statement, the securities of MCAD held by Investor and the intended method of disposition of
the Registrable Shares (which shall be limited to non-underwritten public offerings) as shall be reasonably requested by MCAD to effect
the registration of the Registrable Shares, and Investor shall execute such documents in connection with such registration as MCAD may
reasonably request that are customary of a selling stockholder in similar situations, including providing that MCAD shall be entitled
to postpone and suspend the effectiveness or use of the Registration Statement during any customary blackout or similar period or as permitted
hereunder; and further provided that Investor shall not in connection with the foregoing be required to execute any lock-up or
similar agreement or otherwise be subject to any contractual restriction on the ability to transfer the Registrable Shares. Any failure
by MCAD to file the Registration Statement by the Filing Deadline or to cause the effectiveness of such Registration Statement by the
Effectiveness Deadline shall not otherwise relieve MCAD of its obligations to file or effect the Registration Statement as set forth above
in this Section 7. “Registrable Shares” shall mean, as of any date of determination, the Acquired Shares and any
other equity security of MCAD issued or issuable with respect to the Acquired Shares by way of share split, dividend, distribution, recapitalization,
merger, exchange, replacement or similar event or otherwise.

 

(b) At its
expense MCAD shall:

 

(i) except
for such times as MCAD is permitted hereunder to suspend the use of the prospectus forming part of a Registration Statement, use its commercially
reasonable efforts to keep such registration, and any qualification, exemption or compliance under state securities laws which MCAD determines
to obtain, continuously effective with respect to Investor, and to keep the applicable Registration Statement or any subsequent shelf
registration statement free of any material misstatements or omissions, until the earlier of the following: (A) Investor ceases to
hold any Registrable Shares, (B) the date all Registrable Shares held by Investor may be sold without restriction under Rule 144,
including without limitation, any volume and manner of sale restrictions which may be applicable to affiliates under Rule 144 and without
the requirement for MCAD to be in compliance with the current public information required under Rule 144(c)(1) (or Rule 144(i)(2), if
applicable), and (C) three years from the date of effectiveness of the Registration Statement. The period of time during which MCAD
is required hereunder to keep a Registration Statement effective is referred to herein as the “Registration Period”;

 

    8

     

    

 

(ii) advise
Investor, as expeditiously as possible:

 

(1) when
a Registration Statement or any amendment thereto has been filed with the SEC;

 

(2) after
it shall receive notice or obtain knowledge thereof, of the issuance by the SEC of any stop order suspending the effectiveness of any
Registration Statement or the initiation of any proceedings for such purpose;

 

(3) of
the receipt by MCAD of any notification with respect to the suspension of the qualification of the Registrable Shares included therein
for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and

 

(4) subject
to the provisions in this Subscription Agreement, of the occurrence of any event that requires the making of any changes in any Registration
Statement or prospectus so that, as of such date, the statements therein are not misleading and do not omit to state a material fact required
to be stated therein or necessary to make the statements therein (in the case of a prospectus, in the light of the circumstances under
which they were made) not misleading.

 

Notwithstanding anything to the contrary
set forth herein, MCAD shall not, when so advising Investor of such events, provide Investor with any material, nonpublic information
regarding MCAD other than to the extent that providing notice to Investor of the occurrence of the events listed in (1) through (4)
above constitutes material, nonpublic information regarding MCAD;

 

(iii) use
its commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness of any Registration Statement as
soon as reasonably practicable;

 

(iv) upon
the occurrence of any event contemplated in Section 7(b)(ii)(4) above, except for such times as MCAD is permitted hereunder to
suspend, and has suspended, the use of a prospectus forming part of a Registration Statement, MCAD shall use its commercially reasonable
efforts to as soon as reasonably practicable prepare a post-effective amendment to such Registration Statement or a supplement to the
related prospectus, or file any other required document so that, as thereafter delivered to purchasers of the Registrable Shares included
therein, such prospectus will not include any untrue statement of a material fact or omit to state any material fact necessary to make
the statements therein, in the light of the circumstances under which they were made, not misleading;

 

(v) use
its commercially reasonable efforts to cause all Registrable Shares to be listed on each securities exchange or market, if any, on which
the Shares issued by MCAD have been listed; and

 

(vi) otherwise,
in good faith, cooperate reasonably with, and take such customary actions as may reasonably be requested by the Investor, consistent with
the terms of this Agreement, in connection with the registration of the Registrable Shares.

 

(c) MCAD
will provide a draft of the Registration Statement to Investor for review at least two (2) business days in advance of filing the Registration
Statement; provided that, for the avoidance of doubt, in no event shall MCAD be required to delay or postpone the filing of such Registration
Statement as a result of or in connection with the Investor’s review. In no event shall Investor be identified as a statutory underwriter
in the Registration Statement unless requested by the Commission; provided, that, if the Commission requests that Investor be identified
as a statutory underwriter in the Registration Statement, Investor will have an opportunity to withdraw its Acquired Shares from the Registration
Statement. Notwithstanding the foregoing, if the Commission prevents MCAD from including any or all of the shares proposed to be registered
under the Registration Statement due to limitations on the use of Rule 415 under the Securities Act for the resale of the Acquired Shares
by Investor and the resale of Shares acquired by any Other Investors or otherwise, such Registration Statement shall register for resale
such number of Acquired Shares which is equal to the maximum number of Acquired Shares as is permitted by the Commission. In such event,
the number of Acquired Shares to be registered for Investor and the number of Shares to be registered for such Other Investors named in
the Registration Statement shall be reduced pro rata among all such investors. In the event that MCAD amends the Registration Statement
in accordance with the foregoing, MCAD will use its commercially reasonable efforts to file with the Commission, as promptly as allowed
by the Commission, one or more registration statements to register the resale of those Registrable Shares that were not registered on
the initial Registration Statement, as so amended, and cause such amendment or Registration Statement to become effective as promptly
as practicable.

 

    9

     

    

 

(d) Notwithstanding
anything to the contrary in this Subscription Agreement, MCAD shall be entitled to delay the filing or effectiveness of, or suspend the
use of, the Registration Statement if it determines that in order for the Registration Statement not to contain a material misstatement
or omission, (i) an amendment thereto would be needed to include information that would at that time not otherwise be required in a current,
quarterly, or annual report under the Exchange Act, (ii) the negotiation or consummation of a transaction by MCAD or its subsidiaries
is pending or an event has occurred, which negotiation, consummation or event MCAD’s board of directors reasonably believes would
require additional disclosure by MCAD in the Registration Statement of material information that MCAD has a bona fide business purpose
for keeping confidential and the non-disclosure of which in the Registration Statement would be expected, in the reasonable determination
of MCAD’s board of directors to cause the Registration Statement to fail to comply with applicable disclosure requirements, or (iii)
in the good faith judgment of the majority of MCAD’s board of directors, such filing or effectiveness or use of such Registration
Statement, would be seriously detrimental to the Company and the majority of the MCAD board or directors concludes as a result that it
is essential to defer such filing (each such circumstance, a “Suspension Event”); provided, however,
that MCAD may not delay or suspend the Registration Statement on more than two occasions or for more than forty-five (45) consecutive
calendar days, or more than ninety (90) total calendar days in each case during any twelve-month period. Upon receipt of any written notice
from MCAD of the happening of any Suspension Event during the period that the Registration Statement is effective or if as a result of
a Suspension Event the Registration Statement or related prospectus contains any untrue statement of a material fact or omits to state
any material fact required to be stated therein or necessary to make the statements therein (in light of the circumstances under which
they were made, in the case of the prospectus) not misleading, Investor agrees that (i) it will immediately discontinue offers and
sales of the Registrable Shares under the Registration Statement (excluding, for the avoidance of doubt, sales conducted pursuant to Rule
144) until Investor receives copies of a supplemental or amended prospectus (which MCAD agrees to promptly prepare) that corrects the
misstatement(s) or omission(s) referred to above and receives notice that any post-effective amendment has become effective or unless
otherwise notified by MCAD that it may resume such offers and sales, and (ii) it will maintain the confidentiality of any information
included in such written notice delivered by MCAD unless otherwise required by law or subpoena. If so directed by MCAD, Investor will
deliver to MCAD or, in Investor’s sole discretion destroy, all copies of the prospectus covering the Registrable Shares in Investor’s
possession; provided, however, that this obligation to deliver or destroy all copies of the prospectus covering the Registrable
Shares shall not apply (A) to the extent Investor is required to retain a copy of such prospectus (1) in order to comply with
applicable legal, regulatory, self-regulatory or professional requirements or (2) in accordance with a bona fide pre-existing document
retention policy or (B) to copies stored electronically on archival servers as a result of automatic data back-up.

 

(e) Indemnification.

 

(i) MCAD
agrees to indemnify, to the extent permitted by law, Investor (to the extent a seller under the Registration Statement), its directors,
officers, members, managers, affiliates, shareholders, partners, employees, agents, advisers, and each person who controls Investor (within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act), to the extent permitted by law, against all losses,
claims, damages, liabilities and reasonable and documented out of pocket expenses (including reasonable and documented attorneys’
fees of one law firm) (collectively, “Losses”), as incurred, caused by or arising out of any untrue or alleged untrue statement
of material fact contained in any Registration Statement, prospectus included in any Registration Statement (“Prospectus”)
or preliminary Prospectus or any amendment thereof or supplement thereto or any omission or alleged omission of a material fact required
to be stated therein or necessary to make the statements therein (in the case of a Prospectus, in the light of the circumstances under
which they were made) not misleading, except insofar as the same are caused by or contained in any information or affidavit so furnished
in writing to MCAD by or on behalf of such Investor expressly for use therein. provided, however, that the indemnification contained in
this Section 7(e) shall not apply to amounts paid in settlement of any Losses if such settlement is effected without the consent
of MCAD (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall MCAD be liable for any Losses to the extent
they arise out of or are based upon a violation which occurs : (a) in connection with any failure of such person to deliver or cause to
be delivered a Prospectus made available by MCAD in a timely manner and required to be delivered by such person in connection with the
offer or sale giving rise to such Losses, (b) as a result of offers or sales effected by or on behalf of any person by means of a “free
writing prospectus” (as defined in Rule 405 under the Securities Act) that was not authorized in writing by MCAD, or (c) in connection
with any offers or sales effected by or on behalf of such Investor during a period in which MCAD has suspended use of any Registration
Statement as permitted by this Subscription Agreement.

 

    10

     

    

 

(ii) In
connection with any Registration Statement in which an Investor is participating, such Investor shall furnish (or cause to be furnished)
to MCAD in writing such information and affidavits as MCAD reasonably requests for use in connection with any such Registration Statement
or Prospectus and, to the extent permitted by law, shall indemnify MCAD, its directors and officers and each person or entity who controls
MCAD (within the meaning of the Securities Act) against any Losses resulting from any untrue or alleged untrue statement of material fact
contained or incorporated by reference in any Registration Statement, Prospectus or preliminary Prospectus or any amendment thereof or
supplement thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
therein (in the case of a Prospectus, in the light of the circumstances under which they were made) not misleading, but only to the extent
that such untrue statement or omission is contained (or not contained in, in the case of an omission) in any information or affidavit
so furnished in writing by on behalf of such Investor expressly for use therein; provided, however, that the liability of
each such Investor shall be several and not joint and shall be in proportion to and limited to the net proceeds received by such Investor
from the sale of Registrable Shares giving rise to such indemnification obligation.

 

(iii) Any
person or entity entitled to indemnification herein shall (A) give prompt written notice to the indemnifying party of any claim with respect
to which it seeks indemnification (provided that the failure to give prompt notice shall not impair any person’s or entity’s
right to indemnification hereunder to the extent such failure has not prejudiced the indemnifying party) and (B) unless in such indemnified
party’s reasonable judgment a conflict of interest between such indemnified and indemnifying parties may exist with respect to such
claim, permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party.
If such defense is assumed, the indemnifying party shall not be subject to any liability for any settlement made by the indemnified party
without its consent (but such consent shall not be unreasonably withheld). An indemnifying party who is not entitled to, or elects not
to, assume the defense of a claim shall not be obligated to pay the fees and expenses of more than one counsel for all parties indemnified
by such indemnifying party with respect to such claim, unless in the reasonable judgment of any indemnified party a conflict of interest
may exist between such indemnified party and any other of such indemnified parties with respect to such claim. No indemnifying party shall,
without the consent of the indemnified party, consent to the entry of any judgment or enter into any settlement which cannot be settled
in all respects by the payment of money (and such money is so paid by the indemnifying party pursuant to the terms of such settlement)
or which settlement includes a statement or admission of fault and culpability on the part of such indemnified party or which does not
include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability
in respect to such claim or litigation. 

 

(iv) The
indemnification provided for under this Subscription Agreement shall remain in full force and effect regardless of any investigation made
by or on behalf of the indemnified party or any officer, director or controlling person or entity of such indemnified party and shall
survive the transfer of securities. 

 

(v) If
the indemnification provided under this Section 7(e) from the indemnifying party is unavailable or insufficient to hold harmless
an indemnified party in respect of any losses, claims, damages, liabilities and expenses referred to herein, then the indemnifying party,
in lieu of indemnifying the indemnified party, shall contribute to the amount paid or payable by the indemnified party as a result of
such losses, claims, damages, liabilities and expenses in such proportion as is appropriate to reflect the relative fault of the indemnifying
party and the indemnified party, as well as any other relevant equitable considerations. The relative fault of the indemnifying party
and indemnified party shall be determined by reference to, among other things, whether any action in question, including any untrue or
alleged untrue statement of a material fact or omission or alleged omission to state a material fact, was made by (or not made by, in
the case of an omission), or relates to information supplied by (or not supplied by, in the case of an omission), such indemnifying party
or indemnified party, and the indemnifying party’s and indemnified party’s relative intent, knowledge, access to information
and opportunity to correct or prevent such action. The amount paid or payable by a party as a result of the losses or other liabilities
referred to above shall be deemed to include, subject to the limitations set forth in Sections 7(e)(i), (ii) and (iii) above, any
legal or other fees, charges or expenses reasonably incurred by such party in connection with any investigation or proceeding. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution pursuant
to this Section 7(e)(v) from any person or entity who was not guilty of such fraudulent misrepresentation.

 

    11

     

    

 

(f) MCAD
will provide all customary and commercially reasonable cooperation necessary to (i) enable Investor to resell Registrable Shares pursuant
to the Registration Statement or Rule 144, as applicable, (ii) qualify the Registrable Shares for listing on the primary stock exchange
on which MCAD’s A common stock is then listed, (iii) update or amend the Registration Statement as necessary to include Registrable
Shares and (iv) provide customary notice to holders of Registrable Shares.

 

(g) MCAD
shall use its commercially reasonable efforts, at its sole expense, to cause its legal counsel to (a) issue to the transfer agent with
respect to the Shares (the “Transfer Agent”) and maintain a “blanket” legal opinion instructing the Transfer Agent
that, in connection with a sale of Acquired Shares that are “restricted securities” (i.e., securities issued pursuant to an
exemption from the registration requirements of Section 5 of the Securities Act), the resale of which restricted securities has been registered
pursuant to an effective resale registration statement by the holder thereof named in such resale registration statement, upon receipt
of an appropriate broker representation letter and other such documentation as MCAD’s counsel deems necessary and appropriate and
after confirming compliance with relevant prospectus delivery requirements, it is authorized to remove any applicable restrictive legend
and (b) if the Acquired Shares are not registered pursuant to an effective resale registration statement, issue to the Transfer Agent
a legal opinion to facilitate the sale of the Acquired Shares and removal of any restrictive legends pursuant to any exemption from the
registration requirements of Section 5 of the Securities Act that may be available to a requesting Investor.

 

8. Termination.
This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights and obligations of the parties
hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earliest to occur of (a) such
date and time as the Transaction Agreement is terminated in accordance with its terms, (b) upon the mutual written agreement of each
of the parties hereto to terminate this Subscription Agreement, (c) if the conditions to Closing set forth in Section 3 of
this Subscription Agreement are not satisfied, or are not capable of being satisfied, on or prior to the Closing and, as a result thereof,
the transactions contemplated by this Subscription Agreement will not be or are not consummated at the Closing and (d) the Outside
Date (as defined in the Transaction Agreement and as it may be extended as described therein) if the Closing has not occurred by such
date; provided that nothing herein will relieve any party from liability for any willful breach hereof prior to the time of termination,
and each party will be entitled to any remedies at law or in equity to recover losses, liabilities or damages arising from any such willful
breach. MCAD shall notify the Investor of the termination of the Transaction Agreement promptly after the termination of such agreement.
Upon the termination of this Subscription Agreement in accordance with this Section 8, any monies paid by the Investor to
MCAD in connection herewith shall be promptly (and in any event within one business day after such termination) returned to the Investor.

 

9. Trust
Account Waiver. The Investor acknowledges that MCAD is a blank check company with the powers and privileges to effect a merger, asset
acquisition, reorganization or similar business combination involving MCAD and one or more businesses or assets. The Investor further
acknowledges that, as described in MCAD’s prospectus relating to its initial public offering dated December 21, 2020 (the “IPO
Prospectus”) available at www.sec.gov, substantially all of MCAD’s assets consist of the cash proceeds of MCAD’s
initial public offering and private placement of its securities, and substantially all of those proceeds have been deposited in a trust
account (the “Trust Account”) for the benefit of MCAD, its public shareholders and the underwriter of MCAD’s
initial public offering. Except with respect to interest earned on the funds held in the Trust Account that may be released to MCAD to
pay its tax obligations, if any, the cash in the Trust Account may be disbursed only for the purposes set forth in the IPO Prospectus.
For and in consideration of MCAD entering into this Subscription Agreement, the receipt and sufficiency of which are hereby acknowledged,
the Investor hereby irrevocably waives any and all right, title and interest, or any claim of any kind it has or may have in the future,
in or to any monies held in the Trust Account, and agrees not to seek recourse against the Trust Account as a result of, or arising out
of, this Subscription Agreement; provided, however, that nothing in this Section 9 shall be deemed to limit the Investor’s
right, title, interest or claim to the Trust Account by virtue of the Investor’s (x) record or beneficial ownership of common stock
acquired by any means other than pursuant to this Subscription Agreement or (y) redemption rights in connection with the Transaction with
respect to any shares of common stock of MCAD owned by the Investor.

 

    12

     

    

 

10. Miscellaneous.

 

(a) Neither
this Subscription Agreement nor any rights that may accrue to the Investor hereunder (other than the Shares acquired hereunder, if any)
may be transferred or assigned without the prior written consent of MCAD. Notwithstanding the foregoing, this Subscription Agreement and
any of Investor’s rights and obligations hereunder may be assigned to any fund or account managed by the same investment manager
or investment advisor as the Investor or by an affiliate of such investment manager or investor advisor, without the prior consent of
MCAD, provided that such assignee(s) agrees in writing to be bound by the terms hereof. Upon such assignment by the Investor, the assignee(s)
shall become an Investor hereunder and have the rights and obligations provided for herein to the extent of such assignment; provided
further that, no assignment shall relieve the assigning party of any of its obligations hereunder, including any assignment to any fund
or account managed by the same investment manager or investment advisor as the Investor or by an affiliate of such investment manager
or investment advisor, unless consented to in writing by MCAD (such consent not to be unreasonably conditioned, delayed or withheld).

 

(b) MCAD
may request from the Investor such additional information as MCAD may deem necessary to evaluate the eligibility of the Investor to acquire
the Shares and in connection with the inclusion of the Shares in the Registration Statement, and the Investor shall provide such information
as may reasonably be requested. The Investor acknowledges that MCAD may file a copy of this Subscription Agreement with the SEC as an
exhibit to a current or periodic report or a registration statement of MCAD.

 

(c) The
Investor acknowledges that MCAD, the Company, the Placement Agent (with the Company and the Placement Agent each separately as an express
third-party beneficiary to this Agreement, including each with a right of enforcement) and others will rely on the acknowledgments, understandings,
agreements, representations and warranties of the Investor contained in this Subscription Agreement. Prior to the Closing, the Investor
agrees to promptly notify MCAD, the Company and the Placement Agent if any of the acknowledgments, understandings, agreements, representations
and warranties of the Investor set forth herein are no longer accurate. The Investor acknowledges and agrees that each purchase by the
Investor of Shares from MCAD will constitute a reaffirmation of the acknowledgments, understandings, agreements, representations and warranties
herein (as modified by any such notice) by the Investor as of the time of such purchase.

 

(d) MCAD
and the Placement Agent (as third-party beneficiary with right of enforcement) are each entitled to rely upon this Subscription Agreement
and each is irrevocably authorized to produce this Subscription Agreement or a copy hereof to any interested party in any administrative
or legal proceeding or official inquiry with respect to the matters covered hereby.

 

(e) All
of the representations and warranties contained in this Subscription Agreement shall survive the Closing. All of the covenants and agreements
made by each party hereto in this Subscription Agreement shall survive the Closing.

 

(f) This
Subscription Agreement may not be modified, waived or terminated (other than pursuant to the terms of Section 8 above) except
by an instrument in writing, signed by (i) MCAD, (ii) Investor and (iii) the Company. No failure or delay of either party in exercising
any right or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power,
or any abandonment or discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further
exercise thereof or the exercise of any other right or power. The rights and remedies of the parties and third-party beneficiaries hereunder
are cumulative and are not exclusive of any rights or remedies that they would otherwise have hereunder.

 

    13

     

    

 

(g) This
Subscription Agreement (including the schedule hereto) constitutes the entire agreement, and supersedes all other prior agreements, understandings,
representations and warranties, both written and oral, among the parties, with respect to the subject matter hereof. Except as set forth
in Section 7 and Section 10(c) with respect to the persons referenced therein, this Subscription Agreement shall
not confer any rights or remedies upon any person other than the parties hereto, and their respective successor and assigns.

 

(h) Except
as otherwise provided herein, this Subscription Agreement shall be binding upon, and inure to the benefit of the parties hereto and their
heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements, representations, warranties,
covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon, such heirs, executors, administrators,
successors, legal representatives and permitted assigns.

 

(i) If any
provision of this Subscription Agreement shall be adjudicated by a court of competent jurisdiction to be invalid, illegal or unenforceable,
the validity, legality or enforceability of the remaining provisions of this Subscription Agreement shall not in any way be affected or
impaired thereby and shall continue in full force and effect.

 

(j) This
Subscription Agreement may be executed in one or more counterparts (including by electronic mail or in .pdf) and by different parties
in separate counterparts, with the same effect as if all parties hereto had signed the same document. All counterparts so executed and
delivered shall be construed together and shall constitute one and the same agreement.

 

(k) The
parties hereto acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Subscription
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties
shall be entitled to an injunction or injunctions to prevent breaches of this Subscription Agreement, without posting a bond or undertaking
and without proof of damages, to enforce specifically the terms and provisions of this Subscription Agreement, this being in addition
to any other remedy to which such party is entitled at law, in equity, in contract, in tort or otherwise.

 

(l) This
Subscription Agreement and all disputes, legal actions, suits and proceedings arising out of or relating to this Subscription Agreement
shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to the principles of conflicts
of laws that would otherwise require the application of the law of any other state.

 

(m) THE
PARTIES HERETO IRREVOCABLY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE COURT OF CHANCERY OF THE STATE OF DELAWARE (OR, TO THE EXTENT SUCH
COURT DOES NOT HAVE SUBJECT MATTER JURISDICTION, THE SUPERIOR COURT OF THE STATE OF DELAWARE, OR THE UNITED STATES DISTRICT COURT FOR
THE DISTRICT OF DELAWARE) SOLELY IN RESPECT OF THE INTERPRETATION AND ENFORCEMENT OF THE PROVISIONS OF THIS SUBSCRIPTION AGREEMENT AND
THE DOCUMENTS REFERRED TO IN THIS SUBSCRIPTION AGREEMENT AND IN RESPECT OF THE TRANSACTIONS CONTEMPLATED HEREBY, AND HEREBY WAIVE, AND
AGREE NOT TO ASSERT, AS A DEFENSE IN ANY ACTION, SUIT OR PROCEEDING FOR INTERPRETATION OR ENFORCEMENT HEREOF OR ANY SUCH DOCUMENT THAT
IS NOT SUBJECT THERETO OR THAT SUCH ACTION, SUIT OR PROCEEDING MAY NOT BE BROUGHT OR IS NOT MAINTAINABLE IN SAID COURTS OR THAT VENUE
THEREOF MAY NOT BE APPROPRIATE OR THAT THIS SUBSCRIPTION AGREEMENT OR ANY SUCH DOCUMENT MAY NOT BE ENFORCED IN OR BY SUCH COURTS, AND
THE PARTIES HERETO IRREVOCABLY AGREE THAT ALL CLAIMS WITH RESPECT TO SUCH ACTION, SUIT OR PROCEEDING SHALL BE HEARD AND DETERMINED BY
SUCH A DELAWARE STATE OR FEDERAL COURT. THE PARTIES HEREBY CONSENT TO AND GRANT ANY SUCH COURT JURISDICTION OVER THE PERSON OF SUCH PARTIES
AND OVER THE SUBJECT MATTER OF SUCH DISPUTE AND AGREE THAT MAILING OF PROCESS OR OTHER PAPERS IN CONNECTION WITH SUCH ACTION, SUIT OR
PROCEEDING IN THE MANNER PROVIDED IN THIS SECTION 10(m) OF THIS SUBSCRIPTION AGREEMENT OR IN SUCH OTHER MANNER AS MAY BE PERMITTED
BY LAW SHALL BE VALID AND SUFFICIENT SERVICE THEREOF.

 

    14

     

    

 

(n) EACH
PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS CONTEMPLATED
HEREBY IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES
ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS
SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS SUBSCRIPTION AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (I) NO
REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE
EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER; (II) SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THE
FOREGOING WAIVER; (III) SUCH PARTY MAKES THE FOREGOING WAIVER VOLUNTARILY; AND (IV) SUCH PARTY HAS BEEN INDUCED TO ENTER INTO
THIS SUBSCRIPTION AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS SECTION 10(n).

 

(o) MCAD shall, by 9:00 a.m., New York City
time, on the first (1st) business day immediately following the date of this Subscription Agreement
1, file with the Commission a Current Report on Form 8-K (the “Disclosure Document”) disclosing (i)
all material terms of the transactions contemplated hereby and by the Other Subscription Agreements, (ii) all material terms of the
Transaction and (iii) any other material, nonpublic information that MCAD has provided to the Investor any time prior to the filing
of the Disclosure Document. Upon the issuance of the Disclosure Document, the Investor shall not be in possession of any material,
non-public information received from MCAD or any of its officers, directors or employees or agents (including the Placement Agents)
and the Investor shall no longer be subject to any confidentiality or similar obligations under any current agreement, whether
written or oral with MCAD, the Placement Agents or any of their affiliates. Notwithstanding anything in this Subscription Agreement
to the contrary, MCAD shall not publicly disclose the name of the Investor or any of its affiliates or its investment adviser, or
include the name of the Investor or any of its affiliates or its investment adviser in any press release or in any filing with the
Commission or any regulatory agency or trading market, without the prior written consent of the Investor, except as required by
state or federal securities law, any governmental authority or stock exchange rule, in which case MCAD shall provide the Investor
with prior written notice of such disclosure permitted under hereunder.

 

11. Non-Reliance
and Exculpation. The Investor acknowledges that it is not relying upon, and has not relied upon, any statement, representation or
warranty made by any person, firm or corporation (including, without limitation, the Placement Agent, any of their respective affiliates
or any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing), other than the statements,
representations and warranties of MCAD expressly contained in Section 5 of this Subscription Agreement, in making its investment
or decision to invest in MCAD. The Investor acknowledges and agrees that none of (i) any other investor pursuant to this Subscription
Agreement or any other subscription agreement related to the private placement of the Shares (including the investor’s respective
affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the foregoing), (ii) the
Placement Agent, its affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of
the foregoing, (iii) any other party to the Transaction Agreement, or (iv) any affiliates, or any control persons, officers, directors,
employees, partners, agents or representatives of any of MCAD, the Company or any other party to the Transaction Agreement shall be liable
to the Investor, or to any other investor, pursuant to this Subscription Agreement or any other subscription agreement related to the
private placement of the Shares, the negotiation hereof or thereof or the subject matter hereof or thereof, or the transactions contemplated
hereby or thereby, for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase
of the Shares.

 

 

		1	To clarify, the 8-K which will include the form subscription agreement,
and any MNPI will be filed following the signature of the merger agreement.

 

    15

     

    

 

12. Press
Releases. All press releases or other public communications relating to the transactions contemplated hereby between MCAD and the
Investor, and the method of the release for publication thereof, shall prior to the Closing be subject to the prior approval of (i) MCAD,
and (ii) to the extent such press release or public communication references the Investor by name, the Investor, which approval shall
not be unreasonably withheld or conditioned; provided that neither MCAD nor the Investor shall be required to obtain consent pursuant
to this Section 12 to the extent any proposed release or statement is substantially equivalent to the information that has
previously been made public without breach of the obligation under this Section 12. The restriction in this Section 12
shall not apply to the extent the public announcement is required by applicable securities law, any governmental authority or stock exchange
rule; provided, that in such an event, the applicable party shall use its commercially reasonable efforts to consult with the other party
in advance as to its form, content and timing.

 

13. Notices.
All notices and other communications among the parties shall be in writing and shall be deemed to have been duly given (i) when delivered
in person, (ii) when delivered after posting in the United States mail having been sent registered or certified mail return receipt requested,
postage prepaid, (iii) when delivered by FedEx or other nationally recognized overnight delivery service, or (iv) when delivered by email
(in each case in this clause (iv), solely if receipt is confirmed, but excluding any automated reply, such as an out-of-office notification),
addressed as follows:

 

If to the Investor, to the address provided on the Investor’s
signature page hereto.

 

If to Mountain Crest Acquisition Corp. II., to:

 

311 West 43rd Street

12th Floor

New York, NY 10036

Attention: Suying Liu

Email:        sliu@mcacquisition.com

 

with copies to (which shall not constitute notice), to:

 

Loeb & Loeb LLP

345 Park Avenue

New York, NY 10154

Attention: Mitchell S. Nussbaum, Esq.

Email:        mnussbaum@loeb.com

 

and

 

Better Therapeutics, Inc.

548 Market St #49404

San Francisco, CA 94104

Attention:  Kevin Appelbaum, Chief Executive Officer

Email:        kevin@bettertx.com

 

and

 

Goodwin Procter LLP

100 Northern Avenue

Boston, MA 02210

Attention: Arthur McGivern & Heidi Mayon

Email:        AMcGivern@goodwinlaw.com & HMayon@goodwinlaw.com

 

or to such other
address or addresses as the parties may from time to time designate in writing. Copies delivered solely to outside counsel shall not constitute
notice.

 

[SIGNATURE PAGES FOLLOW]

 

    16

     

    

 

IN WITNESS WHEREOF, the Investor has executed
or caused this Subscription Agreement to be executed by its duly authorized representative as of the date set forth below.

 

	Name of Investor:	 	State/Country of Formation or Domicile:

 

	By:	 	 	 
	Name:	 	 	 
	Title:	 	 	 

 

	Name in which Shares are to be registered (if different):	 	Date: April 6, 2021
	 	 	 
	Investor’s EIN:	 	 
	 	 	 
	Business Address-Street:	 	Mailing Address-Street (if different):
	 	 	 
	City, State, Zip:	 	City, State, Zip:

 

	Attn:  	 	 	Attn: 	 

 

	Telephone No.:	 	Telephone No.:
	Facsimile No.:

E-mail:	 	Facsimile No.:

E-mail:
	 	 	 
	Number of Shares subscribed for:	 	 
	 	 	 
	Aggregate Subscription Amount: $	 	Price Per Share: $10.00

 

You must pay the Subscription Amount by wire transfer
of United States dollars in immediately available funds to the account specified by MCAD in the Closing Notice. To the extent the offering
is oversubscribed, the number of Shares received may be less than the number of Shares subscribed for.

 

[Signature Page to Subscription Agreement]

 

     

     

    

 

IN WITNESS WHEREOF, MCAD has accepted this Subscription
Agreement as of the date set forth below.

 

	 	Mountain Crest Acquisition Corp. II 
	 	 	 
	 	By:  	                      
	 	 	Name:
	 	 	Title:

 

Date:  April 6, 2021

 

[Signature Page to Subscription Agreement]

 

     

     

    

 

SCHEDULE A

 

ELIGIBILITY REPRESENTATIONS OF THE INVESTOR

 

		A.	QUALIFIED INSTITUTIONAL BUYER STATUS

(Please check the applicable subparagraphs):

 

		☐	We are a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act).

 

		B.	INSTITUTIONAL ACCREDITED INVESTOR STATUS

(Please check the applicable subparagraphs):

 

		1.	☐ We are an “accredited investor” (within the meaning
of Rule 501(a) under the Securities Act) or an entity in which all of the equity holders are accredited investors within the meaning
of Rule 501(a) under the Securities Act, and have marked and initialed the appropriate box on the following page indicating the provision
under which we qualify as an “accredited investor.”

 

		2.	☐ We are not a natural person.

 

	
    

    C.
	AFFILIATE STATUS 

 

(Please check the applicable box) SUBSCRIBER:

 

	
    

    ☐
	is: 

         

	☐	is not: 

 

an “affiliate” (as defined in Rule 144 under
the Securities Act) of the Company or acting on behalf of an affiliate of the Company.

 

Rule 501(a), in relevant part, states that an “accredited
investor” shall mean any person who comes within any of the below listed categories, or who the issuer reasonably believes comes
within any of the below listed categories, at the time of the sale of the securities to that person. The Investor has indicated, by marking
and initialing the appropriate box below, the provision(s) below which apply to the Investor and under which the Investor accordingly
qualifies as an “accredited investor.”

 

		☐	Any bank, registered broker or dealer, insurance company, registered investment company, business development company, or small business
investment company;

 

		☐	Any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political
subdivisions for the benefit of its employees, if such plan has total assets in excess of $5,000,000;

 

		☐	Any employee benefit plan, within the meaning of the Employee Retirement Income Security Act of 1974, if a bank, insurance company,
or registered investment adviser makes the investment decisions, or if the plan has total assets in excess of $5,000,000;

 

		☐	Any organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, similar business trust, or partnership,
not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000;

 

		☐	Any trust with assets in excess of $5,000,000, not formed to acquire the securities offered, whose purchase is directed by a sophisticated
person; or

 

		☐	Any entity in which all of the equity owners are accredited investors meeting one or more of the above tests.

 

This page should be completed by the Investor

and constitutes a part of the Subscription Agreement.

 

[Schedule A to Subscription Agreement]Exhibit 10.4

 

LOCK-UP AGREEMENT

 

THIS LOCK-UP AGREEMENT (this “Agreement”) is dated
as of April 6, 2021 by and between the undersigned stockholder (the “Holder”) and Mountain Crest Acquisition Corp.
II, a Delaware corporation (“Parent”).

 

A. Parent, MCAD Merger Sub
Inc., a Delaware corporation and wholly-owned subsidiary of the Parent and Better Therapeutics, Inc., a Delaware corporation (the “Company”),
entered into a Merger Agreement dated as of April 6, 2021 (the “Merger Agreement”).

 

B. Pursuant
to the Merger Agreement, Parent will become the 100% stockholder of the Company.

 

C. The
Holder is the record and/or beneficial owner of certain shares of Company Capital Stock, which will be exchanged for shares of Parent
Common Stock pursuant to the Merger Agreement.

 

D. As
a condition of, and as a material inducement for Parent to enter into and consummate the transactions contemplated by the Merger Agreement,
the Holder has agreed to execute and deliver this Agreement.

 

NOW, THEREFORE, for and in consideration
of the mutual covenants and agreements set forth herein, and other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, the parties, intending to be legally bound, agree as follows:

 

AGREEMENT

 

1. Lock-Up.

 

(a) During
the Lock-up Period, the Holder agrees that it, he or she will not offer, sell, contract to sell, pledge or otherwise dispose of, directly
or indirectly, any of the Lock-up Shares (as defined below), enter into a transaction that would have the same effect, or enter into any
swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of the Lock-up Shares
or otherwise, publicly disclose the intention to make any offer, sale, pledge or disposition, or to enter into any transaction, swap,
hedge or other arrangement, or engage in any Short Sales (as defined below) with respect to the Lock-up Shares.

 

(b) In
furtherance of the foregoing, during the Lock-up Period, the Parent will (i) place a stop order on all the Lock-up Shares, including those
which may be covered by a registration statement, and (ii) notify the Parent’s transfer agent in writing of the stop order and the
restrictions on the Lock-up Shares under this Agreement and direct the Parent’s transfer agent not to process any attempts by the
Holder to resell or transfer any Lock-up Shares, except in compliance with this Agreement.

 

    

     

    

 

(c) For
purposes hereof, “Short Sales” include, without limitation, all “short sales” as defined in Rule 200 promulgated
under Regulation SHO under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and all types of direct
and indirect stock pledges, forward sale contracts, options, puts, calls, swaps and similar arrangements (including on a total return
basis), and sales and other transactions through non-US broker dealers or foreign regulated brokers.

 

(d) The
term “Lock-up Period” means the date that is six (6) months after the Closing Date (as defined in the Merger Agreement).

 

2. Beneficial
Ownership. The Holder hereby represents and warrants that it does not beneficially own, directly or through its nominees (as determined
in accordance with Section 13(d) of the Exchange Act, and the rules and regulations promulgated thereunder), any shares of Parent Common
Stock, or any economic interest in or derivative of such shares, other than those shares of Parent Common Stock [(i)] issued pursuant
to the Merger Agreement)[ or (ii) acquired directly from Mountain Crest Capital LLC pursuant to that Stock Purchase Agreement dated March
5, 2021]. For purposes of this Agreement, the Merger Shares beneficially owned by the Holder, together with any other shares of Parent
Common Stock, and including any securities convertible into, or exchangeable for, or representing the rights to receive Parent Common
Stock, if any, acquired during the Lock-up Period are collectively referred to as the “Lock-up Shares,” provided,
however, that such Lock-up Shares shall not include shares of Parent Common Stock acquired by such Holder in open market transactions
during the Lock-up Period.

 

Notwithstanding the foregoing,
and subject to the conditions below, the undersigned may transfer Lock-Up Shares in connection with (a) transfers or distributions to
the Holder’s direct or indirect affiliates (within the meaning of Rule 405 under the Securities Act of 1933, as amended) or to the
estates of any of the foregoing; (b) transfers by bona fide gift to a member of the Holder’s immediate family or to a trust, the
beneficiary of which is the Holder or a member of the Holder’s immediate family for estate planning purposes; (c) by virtue of the
laws of descent and distribution upon death of the Holder; (d) pursuant to a qualified domestic relations order, (e) transfers to the
Parent’s officers, directors or their affiliates, (f) pledges of Lock-up Shares as security or collateral in connection with a borrowing
or the incurrence of any indebtedness by the Holder, provided, however, that such borrowing or incurrence of indebtedness
is secured by either a portfolio of assets or equity interests issued by multiple issuers, (g) transfers pursuant to a bona fide third-party
tender offer, merger, stock sale, recapitalization, consolidation or other transaction involving a change of control of Parent; provided,
however, that in the event that such tender offer, merger, recapitalization, consolidation or other such transaction is not completed,
the Lock-Up Shares subject to this Agreement shall remain subject to this Agreement, (h) the establishment of a trading plan pursuant
to Rule 10b5-1 promulgated under the Exchange Act; provided, however, that such plan does not provide for the transfer of
Lock-up Shares during the Lock-Up Period, (i) transfers to satisfy tax withholding obligations in connection with the exercise of options
to purchase shares of Parent Common Stock or the vesting of stock-based awards; and (j) transfers in payment on a “net exercise”
or “cashless” basis of the exercise or purchase price with respect to the exercise of options to purchase shares of Parent
Common Stock; provided, however, that, in the case of any transfer pursuant to the foregoing (a) through (e) clauses, it
shall be a condition to any such transfer that (i) the transferee/donee agrees to be bound by the terms of this Agreement (including,
without limitation, the restrictions set forth in the preceding sentence) to the same extent as if the transferee/donee were a party hereto;
and (ii) each party (donor, donee, transferor or transferee) shall not be required by law (including without limitation the disclosure
requirements of the Securities Act of 1933, as amended (the “Securities Act”), and the Exchange Act) to make, and shall
agree to not voluntarily make, any filing or public announcement of the transfer or disposition prior to the expiration of the Lock-Up
Period.

 

    2

     

    

 

3. Representations
and Warranties. Each of the parties hereto, by their respective execution and delivery of this Agreement, hereby represents and warrants
to the other that (a) such party has the full right, capacity and authority to enter into, deliver and perform its respective obligations
under this Agreement, (b) this Agreement has been duly executed and delivered by such party and is a binding and enforceable obligation
of such party and, enforceable against such party in accordance with the terms of this Agreement, and (c) the execution, delivery and
performance of such party’s obligations under this Agreement will not conflict with or breach the terms of any other agreement,
contract, commitment or understanding to which such party is a party or to which the assets or securities of such party are bound. The
Holder has independently evaluated the merits of his/her/its decision to enter into and deliver this Agreement, and such Holder confirms
that he/she/it has not relied on the advice of Company, Company’s legal counsel, or any other person.

 

4. No
Additional Fees/Payment. Other than the consideration specifically referenced herein, the parties hereto agree that no fee, payment
or additional consideration in any form has been or will be paid to the Holder in connection with this Agreement.

 

5. Notices.
Any notices required or permitted to be sent hereunder shall be sent in writing, addressed as specified below, and shall be deemed given:
(a) if by hand or recognized courier service, by 4:00PM on a Business Day, addressee’s day and time, on the date of delivery, and
otherwise on the first Business Day after such delivery; (b) if by email, on the date that transmission is confirmed electronically, if
by 4:00PM on a Business Day, addressee’s day and time, and otherwise on the first Business Day after the date of such confirmation;
or (c) five days after mailing by certified or registered mail, return receipt requested. Notices shall be addressed to the respective
parties as follows (excluding telephone numbers, which are for convenience only), or to such other address as a party shall specify to
the others in accordance with these notice provisions:

 

(a) If
to Company, to:

 

Better Therapeutics, Inc.

548 Market Street, #49404

San Francisco, CA 94104

	 	Attention: 	Kevin Appelbaum
	 	E-mail:	Kevin@bettertx.com

 

with a copy to (which shall not constitute
notice):

Goodwin Procter LLP

100 Norther Avenue

Boston, MA 02210

	 	Attention: 	Arthur R. McGivern
	 	E-mail:	AMcGivern@goodwinlaw.com

 

    3

     

    

 

(b) If
to the Holder, to the address set forth on the Holder’s signature page hereto, with a copy, which shall not constitute notice, to:

_________________________________

_________________________________

_________________________________

Email:

 

or to such other address(es) as any party may
have furnished to the others in writing in accordance herewith.

 

6. Enumeration
and Headings. The enumeration and headings contained in this Agreement are for convenience of reference only and shall not control
or affect the meaning or construction of any of the provisions of this Agreement.

 

7. Counterparts.
This Agreement may be executed in facsimile and in any number of counterparts, each of which when so executed and delivered shall be deemed
an original, but all of which shall together constitute one and the same agreement.

 

8. Successors
and Assigns. This Agreement and the terms, covenants, provisions and conditions hereof shall be binding upon, and shall inure to the
benefit of, the respective heirs, successors and assigns of the parties hereto. The Holder hereby acknowledges and agrees that this Agreement
is entered into for the benefit of and is enforceable by Company and its successors and assigns.

 

9. Severability.
If any provision of this Agreement is held to be invalid or unenforceable for any reason, such provision will be conformed to prevailing
law rather than voided, if possible, in order to achieve the intent of the parties and, in any event, the remaining provisions of this
Agreement shall remain in full force and effect and shall be binding upon the parties hereto.

 

10. Amendment.
This Agreement may be amended or modified by written agreement executed by each of the parties hereto.

 

11. Further
Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to
carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

12. No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their
mutual intent, and no rules of strict construction will be applied against any party.

 

    4

     

    

 

13. Dispute
Resolution. Section 10.8 of the Merger Agreement is incorporated by reference herein to apply with full force to any disputes arising
under this Agreement.

 

14. Governing
Law. Section 10.6 of the Merger Agreement is incorporated by reference herein to apply with full force to any disputes arising under
this Agreement.

 

15. Controlling
Agreement. To the extent the terms of this Agreement (as amended, supplemented, restated or otherwise modified from time to time)
directly conflicts with a provisions in the Merger Agreement, the terms of this Agreement shall control.

 

[Signature Page Follows]

 

    5

     

    

 

IN WITNESS WHEREOF, the parties
hereto have caused this Lock-up Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.

 

	 	Mountain Crest Acquisition Corp. II, 
	 	 	 
	 	By:	                     
	 	Name: 	[●]
	 	Title:	[●]

 

	 	HOLDER:
	 	 	 
	 	By:	                                   
	 	Name: 	 
	 	Title:	 

 

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]